Printer Friendly

HUYA Bioscience International names new vice president, Commercial Planning.

M2 PHARMA-December 16, 2015-HUYA Bioscience International names new vice president, Commercial Planning

(C)2015 M2 COMMUNICATIONS

HUYA Bioscience International, a company involved in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China, has named Scott Garrett MBA as its vice president, Commercial Planning, it was reported yesterday.

Garrett has more than 20 years of commercial experience in both drugs and devices for oncology and cardiovascular disease with companies such as Celladon, Mallinckrodt, Gilead, Johnson and Johnson, Boston Scientific and Nycomed Amersham (now GE Healthcare). His prior responsibilities include sales and marketing, commercial planning, product launch, healthcare economics, reimbursement, advocacy development, life cycle management, and business development for brands such as CERETEC, TAXUS, NATRECOR, RANEXA and OFIRMEV.

Mireille Gillings PhD, CEO of HUYA, said, 'Scott's commercial experience in oncology and cardiovascular disease will play a key role as HUYA transitions from a development to a commercial-stage company. We welcome him to the HUYA senior management team, where he will assume responsibility for the Company's increasing commercial focus.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 16, 2015
Words:182
Previous Article:Trident Brands names new special advisor to Brain Armor.
Next Article:Bristol-Myers Squibb signs collaboration agreement with the University of California.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters